亚甲基四氢叶酸还原酶基因型在多发性骨髓瘤发病机制中不起作用。

Methylenetetrahydrofolate reductase genotype does not play a role in multiple myeloma pathogenesis.

作者信息

González-Fraile Maria I, García-Sanz Ramoń, Mateos Maria V, Balanzategui Ana, González Marcos, Váquez Lourdes, San Miguel Jesús F

机构信息

Servicio de Hematología, Hospital Clínico Universitario de Salamanca, Centro de Investigación del Cáncer (CIC), Paseo de San Vicente 58-182, 37007 Salamanca, Spain.

出版信息

Br J Haematol. 2002 Jun;117(4):890-2. doi: 10.1046/j.1365-2141.2002.03502.x.

DOI:10.1046/j.1365-2141.2002.03502.x

PMID:12060127

Abstract

Methylenetetrahydrofolate reductase (MTHFR) plays an important role in carcinogenesis. A decreased incidence of cancer has been reported in the presence of MTHFR 677TT, 1298AC and 1298CC polymorphic variants. We have analysed the MTHFR genotype in 107 multiple myeloma (MM) patients and 86 controls. The MM and control polymorphisms frequencies were: 34% and 48% for 677CC, 53% and 41% for 677CT, 12% and 11% for 677TT; 36% and 43% for 1298AA, 51% and 44% for 1298AC; and 12% and 13% for 1298CC respectively. No statistically significant differences were observed. In addition, no differences were seen according to MM stage, presence of p16 gene hypermethylation or response to treatment.

摘要

亚甲基四氢叶酸还原酶（MTHFR）在致癌过程中起重要作用。据报道，存在MTHFR 677TT、1298AC和1298CC多态性变体时癌症发病率会降低。我们分析了107例多发性骨髓瘤（MM）患者和86例对照者的MTHFR基因型。MM组和对照组的多态性频率分别为：677CC为34%和48%，677CT为53%和41%，677TT为12%和11%；1298AA为36%和43%，1298AC为51%和44%；1298CC为12%和13%。未观察到统计学上的显著差异。此外，根据MM分期、p16基因高甲基化的存在情况或治疗反应，均未发现差异。